FAP PET/CT for Staging Patients With Breast Cancer

Starting soon · Phase 2

Conditions studied: Breast Cancer Detection

In brief

This study aims to evaluate the clinical utility of \[68Ga\]Ga-FAP-2268 PET/CT for disease staging and assessment in patients with high-risk primary breast cancer. By targeting fibroblast activation protein (FAP), this novel imaging approach may offer improved tumor visualization compared to conventional imaging, which may help improve treatment planning.

Key facts

Study ID

NCT07523607

Run by

Odense University Hospital

People needed

65

Starts

2026-06-01

Expected to finish

2029-01-01

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and females ≥ 18 years
• Biopsy-verified newly diagnosed breast cancer
• Can read and understand Danish
• Capable of providing written and informed consent
• Undergoing a routine [¹⁸F]FDG PET/CT scan as part of the clinical standard diagnostic workup

You may not qualify if…

• Pregnant or lactating women
• Not able to participate in the conduct of the scan due to any reason ( e.g., claustrophobia or inability to lie still for entire imaging time)
• Ongoing oncological treatment for another cancer
• History of allergic reactions / hypersensitivity attributed to [⁶⁸Ga]Ga-FAP-2286.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.